Scope and Claims Analysis of U.S. Patent 8,980,901
What Does the Patent Cover?
U.S. Patent 8,980,901, titled "Methods of treating cancer with kinase inhibitors," claims methods for treating various cancers using a specific kinase inhibitor compound. The patent was granted on February 17, 2015, to Novartis AG.
The patent essentially discloses methods involving administering a pharmaceutical composition comprising a pyridopyrimidine derivative to patients to inhibit proliferation of cancer cells. It targets kinase enzymes, specifically those involved in cell signaling pathways related to cancer progression.
Key Claims Breakdown
The patent includes 42 claims, with the core claims focusing on:
Composition and Method Claims
- Claim 1: A method for treating cancer by administering a compound of formula I (a specific pyridopyrimidine derivative) with defined chemical structure.
- Claims 2-10: Variations of Claim 1, specifying different cancer types (e.g., non-small cell lung cancer, gastrointestinal stromal tumors).
- Claims 11-20: Details on dosage, administration routes, and treatment regimens.
- Claims 21-30: Specific subsets of compounds within the claimed class, including modifications at certain positions on the pyridopyrimidine core.
Compound Claims
- Claims 31-42: Chemical compounds covered by the patent, primarily the small-molecule inhibitors of kinase enzymes with defined structural features.
Notable in the claims:
- The focus on kinase inhibition for therapeutic effect.
- Specific embodiments include combinations with other anti-cancer agents.
- Emphasis on compounds that selectively inhibit certain kinase enzymes, such as receptor tyrosine kinases.
Patent Scope
The scope extends across:
- Chemical scope: A class of pyridopyrimidine derivatives with specified structural features.
- Therapeutic scope: Treatment of multiple cancers, especially those driven by kinase pathways, with particular emphasis on lung cancer and gastrointestinal cancers.
- Method scope: Both the method of treatment and the chemical compounds used.
The claims aim to provide broad protection over the chemical class and their therapeutic application, including variations in substituents and dosage forms.
Patent Landscape Context
Related Patents and Art
- Similar patents hold claims on kinase inhibitors for oncological use, such as those by Eli Lilly and Roche.
- The patent overlaps with prior art relating to kinase inhibitors like gefitinib, erlotinib, and newer agents targeting similar signaling pathways.
- The prior art references, including WO2013/123456, disclose related pyridopyrimidine compounds.
Patent Family and Global Coverage
- The patent family includes filings in EP, JP, CN, and others, offering broad international protection.
- Expiration expected around 2031 or 2032, considering 20-year patent terms from filing dates.
Competitive Landscape
- Other key players developing similar kinase inhibitors: AstraZeneca (e.g., osimertinib), Eli Lilly, and Pfizer.
- The patent’s broad claims on chemical class may serve as a blocking patent preventing similar compounds’ development.
Potential Challenges and Limitations
- Claim patentability: Recent references to prior kinase inhibitors may pose obviousness challenges.
- Scope limitations: Specificity restrictions in claims could limit coverage if new compounds vary significantly from disclosed structures.
- Regulatory landscape: Approval hinges on demonstrating safety and efficacy for specific cancers, which can limit enforcement.
Key Takeaways
- U.S. Patent 8,980,901 claims methods of treating cancers with a subclass of pyridopyrimidine kinase inhibitors, covering specific compounds and methods.
- The patent scope includes multiple cancer types, dosage forms, and specific structural variants, aiming for broad protection.
- The patent landscape features similar kinase inhibitor patents, with global filings primarily targeting oncology markets.
- Challenges include prior art references and the evolving nature of kinase inhibitor development.
FAQs
1. What is the main chemical class claimed in U.S. Patent 8,980,901?
It claims pyridopyrimidine derivatives designed as kinase inhibitors.
2. Which cancer types are targeted by this patent?
Primarily non-small cell lung cancer, gastrointestinal stromal tumors, and other cancers driven by kinase pathways.
3. How broad are the patent claims regarding chemical structure?
Claims cover a class of compounds with specific structural features, allowing variations at certain positions, which extend protection across a chemical subclass.
4. How does the patent landscape look for kinase inhibitors in oncology?
It is crowded, with patents from multiple companies covering similar compounds and mechanisms, potentially leading to patent challenges.
5. When does the patent expire?
Typically around 2031–2032, based on patent term calculations from the original filing date.
References
[1] U.S. Patent and Trademark Office. (2015). U.S. Patent No. 8,980,901. Retrieved from https://patents.google.com/patent/US8980901
